Features Thursday, November 27, 2014 - 05:30
The News Minute | November 27, 2014 | 5:15 pm IST GlaxoSmithKline Plc (GSK), one of the world’s leading research based pharmaceutical and healthcare companies has come out with an experimental Ebola vaccine that has passed an early safety test. The vaccine was administered to 20 healthy volunteers who received it in an early stage clinical trial and it caused no serious side effects and produced an immune response in all of them. The National Institute of Allergy and Infectious Diseases (NIAID) which is conducting the 48 week trial in Bethesda, Maryland, said that the immune response offered hope that the vaccine may be effective. According to a report in livemint, the vaccine was developed at by Okairos, a biotechnology company acquired by GSK. The vaccine contains genetic material from two Ebola strains. Since exposing the volunteers aged 18-50, to Ebola is out of the question, the researchers measure the effectiveness by checking the production of anti-Ebola antibodies and immune-system T cells. Attempts are ongoing to understand the dosage required to trigger immunity as higher the dosage is, the more challenging and expensive it would be to produce the vaccine in bulk.